P&K Skin Research Center
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
P&K Skin Research Center runs a clinical testing laboratory that measures whether cosmetics, beauty devices, and health supplements actually do what their makers claim, running both human-subject trials and lab-based tests.
Its clients are domestic and international manufacturers and distributors of cosmetics, beauty devices, and health functional foods. Listed on KOSDAQ, Korea's tech and small-cap board, the company earns the large majority of its revenue from cosmetic human-application trials, with other human trials and lab tests making up the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Korean regulations require cosmetics makers to obtain certified efficacy evidence from the Ministry of Food and Drug Safety before making functional claims, which underpins demand for third-party testing services like those P&K provides.
P&K Skin Research Center in five facts
What does P&K Skin Research Center do?
P&K Skin Research Center runs a clinical testing laboratory that measures whether cosmetics, beauty devices, and health supplements actually do what their makers claim, running both human-subject trials and lab-based tests.
Where is P&K Skin Research Center listed and in which sector?
P&K Skin Research Center (Korean name: 피엔케이피부임상연구센타) trades under KRX code 347740 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is P&K Skin Research Center?
Its market capitalisation was US$37.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were P&K Skin Research Center's latest annual revenue and operating profit?
For fiscal year 2025, P&K Skin Research Center reported revenue of US$17.2M, operating profit of US$3M and net income of US$3.5M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was up 27.7% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Cash/in-kind dividend decision
P&K Skin Research Center declared a cash dividend of US$0.03 per share, equal to about 1.98% of the recent share price.
Dividend · Mar 5 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
P&K Skin Research Center reported consolidated results for FY2025: revenue of US$16M (+27.6% year on year), operating profit of US$2.76M (+52.5% year on year) and net income of US$3.23M (−19.2% year on year).
Earnings · Feb 26